title: Hemorheological alterations and hypercoagulable state in deep vein thrombosis.
abstract: Deep vein thrombosis (DVT) seems to be related to a hypercoagulation and definite hemorheological alterations, but the importance of these alterations in the development of thrombotic events in the deep vein system has not been established. The present study examines both aspects in a group of 55 patients with DVT; the presence of a hypercoagulable state was assessed by quantifying the prothrombin fragment 1+2 (F1+2) and the thrombin-antithrombin III complex (T-AT), and the main hemorheological parameters were evaluated in the acute state and 6 and 12 months later. The results show marked hemorheological, F1+2, and TAT alterations in the acute phase. After 12 months the pattern shows a modest improvement, but erythrocyte aggregation, fibrinogen, F1+2 and T-AT remain increased with respect to the control group (8.51 +/- 1.43; 331 +/- 81 mg/dl; 1.33 +/- 0.60 nmol/l; 3.54 +/- 1.71 ng/ml vs. 8.10 +/- 1.40; 230 +/- 38; 0.94 +/- 0.40; 1.56 +/- 0.59, respectively). These data suggest that the thrombotic event could be influenced by the previous rheological situation and hypercoagulable state.
authors.affiliation: Hemorheology Unit, Clinical Pathology, LA FE Hospital, Valencia, Spain.
authors.forename: Y
authors.initials: Y
authors.lastname: Mira
authors.forename: A
authors.initials: A
authors.lastname: Vayá
authors.forename: M
authors.initials: M
authors.lastname: Martínez
authors.forename: P
authors.initials: P
authors.lastname: Villa
authors.forename: M L
authors.initials: ML
authors.lastname: Santaolaria
authors.forename: F
authors.initials: F
authors.lastname: Ferrando
authors.forename: J
authors.initials: J
authors.lastname: Aznar
mesh_terms: D000074:Acenocoumarol / Q000627:therapeutic use; D000208:Acute Disease; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D001809:Blood Viscosity; D003289:Convalescence; D004903:Erythrocyte Aggregation; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D018056:Hemorheology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D011516:Prothrombin / Q000032:analysis; D019851:Thrombophilia / Q000139:chemically induced / Q000150:complications* / Q000503:physiopathology; D013924:Thrombophlebitis / Q000097:blood* / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D014947:Wounds and Injuries / Q000150:complications